Miguel Malespin, MD
Hepatology · Tampa, FLNPI 1568639326
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $55,990 of the $63,987 with a category attached, or 87.5%. Gilead accounts for 60.4% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2019 at $50,331 and has fallen 99.8% since, to $121 in 2021.
Across 66 payments — averaging $969.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$39K
- Intercept Pharmaceuticals, Inc.$25K
- Dova Pharmaceuticals$126
- Cook Medical LLC$121
- Exelixis Inc.$111
Across 29 payments — averaging $4737.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Intercept Pharmaceuticals, Inc.$130K
- Novo Nordisk AS$8K
What the payments were for
- Speaking & faculty fees$55,99088%
- Travel & lodging$5,9099%
- Food & beverage$2,0883%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 44 | $38,624 |
| Intercept Pharmaceuticals, Inc. | 19 | $25,004 |
| Dova Pharmaceuticals | 1 | $126 |
| Cook Medical LLC | 1 | $121 |
| Exelixis Inc. | 1 | $111 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few hepatology providers in Floridato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 480 | $1,508,519 |
| EpclusaSofosbuvir/Velpatasvir | 32 | $750,927 |
| Trientine Hcl | 14 | $90,134 |
| Envarsus XrTacrolimus | 52 | $50,833 |
| Ursodiol | 152 | $22,378 |
| Tacrolimus | 145 | $13,896 |
| Entecavir | 42 | $6,268 |
| Mycophenolate Mofetil | 57 | $4,972 |
| Cyclosporine ModifiedCyclosporine, Modified | 11 | $2,094 |
| Mycophenolic AcidMycophenolate Sodium | 15 | $1,857 |
| Lactulose | 50 | $1,708 |
| Nadolol | 26 | $1,244 |
| Spironolactone | 85 | $864 |
| Azathioprine | 34 | $655 |
| Carvedilol | 100 | $391 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadEpclusa | $38,624 | $750,92732 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hepatology providers in Floridaon file to place this against a meaningful peer group, so we don't.
Other hepatology in Tampa
- Basem AlkurdiTampa$18K
- Brett FortuneMiami$147K
- Shady GuirguisOrlando$100K
- Cynthia LevyMiami$88K
- Arvind Rangarajan MuraliOrlando$46K
- Christopher ObrienWeston$18K
- Flavia MendesMiami$6K
- Leopoldo ArosemenaMiami$4K
- Xaralambos ZervosOrlando$3K
- Mina AwadallahBoca Raton$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.